{
    "clinical_study": {
        "@rank": "26667", 
        "arm_group": [
            {
                "arm_group_label": "Baseline", 
                "arm_group_type": "No Intervention", 
                "description": "Premenopausal women will undergo baseline sampling in each the follicular and luteal phase. Postmenopausal women will undergo baseline sampling one time."
            }, 
            {
                "arm_group_label": "TFV 1% Gel", 
                "arm_group_type": "Experimental", 
                "description": "Participants will vaginally insert 1 applicator of TFV gel followed by a 2nd applicator 2 hours later.  Each applicator contains 4.4 gm of TFV 1% gel.\nPremenopausal women will undergo sampling after TFV gel use in each the follicular and luteal phase.  Postmenopausal women will undergo sampling after TFV gel use one time."
            }, 
            {
                "arm_group_label": "Estradiol  Vaginal Cream", 
                "arm_group_type": "Experimental", 
                "description": "Post menopausal women only: Participants will insert 2 grams of estradiol cream into the vagina every night for 14 days and then one gram of estradiol cream into the vagina every other night"
            }, 
            {
                "arm_group_label": "TFV 1% gel and estradiol cream", 
                "arm_group_type": "Experimental", 
                "description": "Postmenopausal women only: Participants will vaginally insert 1 applicator of TFV gel followed by a 2nd applicator 2 hours later. Each applicator contains 4.4 gm of TFV 1% gel.  In addition, participants will one gram of estradiol cream into the vagina every other night."
            }
        ], 
        "brief_summary": {
            "textblock": "Purpose of the study is to assess tenofovir (TFV) PK and PD endpoints, cervicovaginal safety\n      parameters, susceptibility to HIV-1 infection, and objective measures of vaginal applicator\n      use in premenopausal and postmenopausal women."
        }, 
        "brief_title": "Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity", 
        "condition": "HIV Prevention", 
        "detailed_description": {
            "textblock": "Premenopausal women: Baseline blood and genital samples will be taken in the follicular and\n      luteal phase (visits 2 and 3).  The participant will be given TFV gel and instructed to\n      insert two doses, separated by 2 hours, and return to the clinic 3 hours after the second\n      insertion for blood and genital samples (visits 4/4a and 5/5a).\n\n      Postmenopausal women: Premenopausal women: Baseline blood and genital samples will be taken\n      (visit 2).  The participant will be given TFV gel and instructed to insert two doses,\n      separated by 2 hours, and return to the clinic 3 hours after the second insertion for blood\n      and genital samples (visit 3/3a).  Estradiol cream will be distributed at visit 4.  Post\n      estradiol blood and genital samples will be taken at Visit 5.  The participant will given\n      TFV gel and instructed to insert 2 doses as before, while continuing to use the estradiol\n      cream.  Post TFV gel and estradiol cream blood and genital samples will be taken (visit\n      6/6a)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: All volunteers\n\n          -  In good healthsignificant systemic disease\n\n          -  Not at risk of an STI, meaning: In a monogamous heterosexual or same sex relationship\n             for at least the last four months with a partner who is not known to be HIV positive\n             and has no known risks for STIs OR sexually abstinent\n\n          -  Willing and able to comply with study procedures\n\n          -  Normal Pap smear (by written report) in the past year.\n\n        Inclusion Criteria: Premenopausal volunteers\n\n          -  21-to-45 years of age\n\n          -  Not at risk for pregnancy, meaning:\n\n          -  Regular menstrual cycles (every 24 - 35 days)\n\n          -  Luteal phase P level of greater than or equal to 3 ng/ml\n\n        Inclusion Criteria: Postmenopausal volunteers\n\n          -  46-89 years of age OR both ovaries removed at least 30 days prior to Visit 1\n\n          -  No menstrual periods/vaginal bleeding in the past 12 months OR both ovaries removed\n             at least 30 days prior to Visit 1\n\n          -  FSH level of greater than or equal to 20 MIU/ml\n\n        Exclusion Criteria: All volunteers\n\n          -  Clinically significant history of an abnormal Pap smear in the past year\n\n          -  Surgery or biopsy of the vagina or cervix within 30 days\n\n          -  Current STI or lower genital tract infection\n\n          -  Current use of chronic immunosuppressants\n\n          -  Current presence of vulvar, anal and/or vaginal genital warts\n\n          -  Current tobacco use of any amount\n\n          -  History of sensitivity/allergy to any component of the study product, topical\n             anesthetic, or allergy to silver nitrate and/or Monsel's solution\n\n          -  Known bleeding disorder that could lead to prolonged or continuous bleeding\n\n          -  Grade 1 or higher laboratory abnormality, per the August 2009 update of the DAIDS\n             Table for Grading the Severity of Adverse Events\n\n          -  Systemic use in the last two weeks or anticipated use during the study of any of the\n             following: corticosteroids, antibiotics, anticoagulants or other drugs known to\n             prolong bleeding and/or clotting, antifungals, antivirals or antiretrovirals.\n\n          -  Investigator discretion\n\n          -  Current participation in any other drug or device study\n\n        Exclusion Criteria: Premenopausal women\n\n          -  Use of DMPA in last six months\n\n          -  Use of any other hormonal contraceptive method without 2 subsequent, normal menses\n             since stopping hormonal contraceptives\n\n          -  Current use of copper IUD\n\n          -  Currently pregnant or pregnancy within the past 3 months\n\n          -  Currently breastfeeding/having breastfed an infant in the last 2 months\n\n        Exclusion Criteria: Postmenopausal women\n\n          -  Use of any hormonal medications in the past 30 days\n\n          -  Contraindications to vaginal estrogen cream"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "89 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01810315", 
            "org_study_id": "A12-124"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "TFV 1% Gel", 
                    "TFV 1% gel and estradiol cream"
                ], 
                "intervention_name": "TFV 1% gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Estradiol  Vaginal Cream", 
                    "TFV 1% gel and estradiol cream"
                ], 
                "intervention_name": "Estradiol vaginal cream", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Estradiol", 
                "Polyestradiol phosphate", 
                "Estradiol valerate", 
                "Estradiol 3-benzoate", 
                "Estradiol 17 beta-cypionate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 11, 2014", 
        "location": {
            "contact": {
                "last_name": "Cooper", 
                "phone": "757-446-8487"
            }, 
            "facility": {
                "address": {
                    "city": "Norfolk", 
                    "country": "United States", 
                    "state": "Virginia", 
                    "zip": "23507"
                }, 
                "name": "Clinical Research Center, Eastern Virginia Medical School"
            }, 
            "investigator": {
                "last_name": "Andrea Thurman, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Influence of Female Reproductive Cycle and Menopause on Cervicovaginal Tissue Susceptibility to HIV-1 Infections and Tenofovir 1% Gel Activity", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Concentrations of tenofovir in plasma, vaginal aspirate, and genital tissue", 
                "safety_issue": "No", 
                "time_frame": "3 hours after dosing"
            }, 
            {
                "measure": "Concentrations of TFV-DP in genital tissue", 
                "safety_issue": "No", 
                "time_frame": "3 hours after dosing"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01810315"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "CONRAD", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CONRAD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}